Evidence map›Paper›PMID 35999234›Full record

ArticleScientific reports2022

Harmonisation of in-silico next-generation sequencing based methods for diagnostics and surveillance.

J Nunez-Garcia, M AbuOun, N Storey, M S Brouwer, J F Delgado-Blas, S S Mo, N Ellaby, K T Veldman, M Haenni, P Châtre and 12 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 10 institutions in 6 countries.

J Nunez-GarciaAnimal and Plant Health Agency (APHA), Weybridge, UK.
M AbuOunAnimal and Plant Health Agency (APHA), Weybridge, UK.
N StoreyAnimal and Plant Health Agency (APHA), Weybridge, UK.
M S BrouwerWageningen Bioveterinary Research (WBVR), Lelystad, The Netherlands.
J F Delgado-BlasUniversidad Complutense de Madrid (UCM), Madrid, Spain.
S S MoNorwegian Veterinary Institute (NVI), Oslo, Norway.
N EllabyPublic Health England (PHE), London, UK.
K T VeldmanWageningen Bioveterinary Research (WBVR), Lelystad, The Netherlands.
M HaenniAgence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), Unité Antibiorésistance et Virulence Bactériennes, Maisons-Alfort, France.
P ChâtreAgence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), Unité Antibiorésistance et Virulence Bactériennes, Maisons-Alfort, France.
J Y MadecAgence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), Unité Antibiorésistance et Virulence Bactériennes, Maisons-Alfort, France.
J A HammerlGerman Federal Institute for Risk Assessment (BfR), Berlin, Germany.
C SernaUniversidad Complutense de Madrid (UCM), Madrid, Spain.
M GetinoUniversity of Surrey (UoS), Guildford, UK.
R La RagioneUniversity of Surrey (UoS), Guildford, UK.
T NaasAssistance Publique Hopitaux de Paris, Paris, France.
A A TelkeNorwegian Veterinary Institute (NVI), Oslo, Norway.
P GlaserInstitute Pasteur, EERA Unit, Paris, France.
M SundeNorwegian Veterinary Institute (NVI), Oslo, Norway.
B Gonzalez-ZornUniversidad Complutense de Madrid (UCM), Madrid, Spain.
M J EllingtonPublic Health England (PHE), London, UK.
M F AnjumAnimal and Plant Health Agency (APHA), Weybridge, UK. muna.anjum@apha.gov.uk.
Animal and Plant Health Agency · GBAgence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail · FRNorwegian Veterinary Institute · NOUniversidad Complutense de Madrid · ESPublic Health England · GBUniversity of Surrey · GBWageningen University & Research · NLAssistance Publique – Hôpitaux de Paris · FRFederal Institute for Risk Assessment · DEInstitut Pasteur · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Improvements in cost and speed of next generation sequencing (NGS) have provided a new pathway for delivering disease diagnosis, molecular typing, and detection of antimicrobial resistance (AMR). Numerous published methods and protocols exist, but a lack of harmonisation has hampered meaningful comparisons between results produced by different methods/protocols vital for global genomic diagnostics and surveillance. As an exemplar, this study evaluated the sensitivity and specificity of five well-established in-silico AMR detection software where the genotype results produced from running a panel of 436 Escherichia coli were compared to their AMR phenotypes, with the latter used as gold-standard. The pipelines exploited previously known genotype-phenotype associations. No significant differences in software performance were observed. As a consequence, efforts to harmonise AMR predictions from sequence data should focus on: (1) establishing universal minimum to assess performance thresholds (e.g. a control isolate panel, minimum sensitivity/specificity thresholds); (2) standardising AMR gene identifiers in reference databases and gene nomenclature; (3) producing consistent genotype/phenotype correlations. The study also revealed limitations of in-silico technology on detecting resistance to certain antimicrobials due to lack of specific fine-tuning options in bioinformatics tool or a lack of representation of resistance mechanisms in reference databases. Lastly, we noted user friendliness of tools was also an important consideration. Therefore, our recommendations are timely for widespread standardisation of bioinformatics for genomic diagnostics and surveillance globally.

Indexed as

Anti-Bacterial AgentsEscherichia coli InfectionsComputational BiologyDrug Resistance, BacterialEscherichia coliHigh-Throughput Nucleotide SequencingHumansMicrobial Sensitivity TestsAnti-Bacterial Agents

Identifiers

PMID35999234
PMCPMC9396611
OpenAlexW4292738232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.